AU2001252884A1 - Method of dopamine inhibition using l-threo-methylphenidate - Google Patents

Method of dopamine inhibition using l-threo-methylphenidate

Info

Publication number
AU2001252884A1
AU2001252884A1 AU2001252884A AU5288401A AU2001252884A1 AU 2001252884 A1 AU2001252884 A1 AU 2001252884A1 AU 2001252884 A AU2001252884 A AU 2001252884A AU 5288401 A AU5288401 A AU 5288401A AU 2001252884 A1 AU2001252884 A1 AU 2001252884A1
Authority
AU
Australia
Prior art keywords
threo
methylphenidate
dopamine inhibition
dopamine
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001252884A
Inventor
Ross Baldessarini
Alexander Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mclean Hospital Corp
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of AU2001252884A1 publication Critical patent/AU2001252884A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
AU2001252884A 2000-04-12 2001-04-11 Method of dopamine inhibition using l-threo-methylphenidate Abandoned AU2001252884A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09547767 2000-04-12
US09/547,767 US6221883B1 (en) 2000-04-12 2000-04-12 Method of dopamine inhibition using l-threo-methylphenidate
PCT/US2001/005826 WO2001078729A1 (en) 2000-04-12 2001-04-11 Method of dopamine inhibition using l-threo-methylphenidate

Publications (1)

Publication Number Publication Date
AU2001252884A1 true AU2001252884A1 (en) 2001-10-30

Family

ID=24186038

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001252884A Abandoned AU2001252884A1 (en) 2000-04-12 2001-04-11 Method of dopamine inhibition using l-threo-methylphenidate

Country Status (5)

Country Link
US (1) US6221883B1 (en)
EP (1) EP1292305B1 (en)
AU (1) AU2001252884A1 (en)
DE (1) DE60128911T2 (en)
WO (1) WO2001078729A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US9098297B2 (en) * 1997-05-08 2015-08-04 Nvidia Corporation Hardware accelerator for an object-oriented programming language
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US6480205B1 (en) 1998-07-22 2002-11-12 Nvidia Corporation Method and apparatus for occlusion culling in graphics systems
US6844880B1 (en) 1999-12-06 2005-01-18 Nvidia Corporation System, method and computer program product for an improved programmable vertex processing model with instruction set
US7209140B1 (en) 1999-12-06 2007-04-24 Nvidia Corporation System, method and article of manufacture for a programmable vertex processing model with instruction set
US20020103162A1 (en) * 2000-08-28 2002-08-01 Mel Epstein Use of threo-methylphenidate compounds to enhance memory
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20060127421A1 (en) * 2004-12-09 2006-06-15 Celgene Corporation Treatment using D-threo methylphenidate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
CA2272373A1 (en) * 1996-12-13 1998-06-18 Medeva Europe Limited The preparation of enantiomerically-enriched threo-methylphenidate

Also Published As

Publication number Publication date
WO2001078729A1 (en) 2001-10-25
US6221883B1 (en) 2001-04-24
EP1292305A1 (en) 2003-03-19
EP1292305B1 (en) 2007-06-13
DE60128911T2 (en) 2008-02-21
EP1292305A4 (en) 2004-04-07
DE60128911D1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001271530A1 (en) Method of hard tissue repair
AUPQ687600A0 (en) A method of detection
AU2002222172A1 (en) Method of retrieving entities
AU2001286983A1 (en) Method of treatment
AU2002326949A1 (en) Method for the inhibition of methanogenesis
AU2002222627A1 (en) Tak1 inhibitors
AU2001252884A1 (en) Method of dopamine inhibition using l-threo-methylphenidate
GB2366639B (en) Method of comparing parts
AU2001288092A1 (en) Method of crystallization
AU2001287668A1 (en) Method for the sterilisation of objects
AUPQ904100A0 (en) Method of encryption
PL346034A1 (en) Method of obtaining substituted banzoylcyanide aminohydrazones
AU2001262177A1 (en) Method of treatment
AU2001268853A1 (en) Biocatalyst inhibitors
AU2002220757A1 (en) Method for obtaining azaerythromycin
AU2003299137A1 (en) Inhibition of metallo-beta-lactamase
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU2002228911A1 (en) Methods for inhibiting pain
AU2002305868A1 (en) Inhibitors of reggamma
AU2001246862A1 (en) Method of detecting cancer
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU7933800A (en) Method of selecting for an inhibitor of rmlc